Q-omics provides the consensus-scored CCDC13 profile across patient tissues and cancer cell-line models. CCDC13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC13 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CCDC13 RNA expression shows 16,341 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where CCDC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC13 survival associations across molecular data types. CCDC13 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC13 RNA expression–survival associations across cancer types. High CCDC13 expression shows unfavorable associations in KICH, LUSC, KIRC and LAML, but favorable associations in KIRP and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC13 RNA expression.
This table summarizes CCDC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC13 shows lower tumor expression in KIRC, THCA, LUSC, LUAD, COAD and KICH. The KIRC box plot shows higher CCDC13 RNA expression in normal versus tumor tissue (log2 FC = −0.811, t-test p < 0.001).
This table shows molecular features associated with CCDC13 in patient tissues and cancer cell lines. In patient samples, CCDC13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
